Korean J Intern Med.  2013 Sep;28(5):515-524. 10.3904/kjim.2013.28.5.515.

Current status of chemotherapy for the treatment of advanced biliary tract cancer

• Sasaki T
• Isayama H
• Nakai Y
• Koike K

• KMID: 1780097
• DOI: http://doi.org/10.3904/kjim.2013.28.5.515

Abstract

Chemotherapy is indispensable for the treatment of advanced biliary tract cancer. Recently, reports regarding first-line chemotherapy have increased, and first-line chemotherapy treatment has become gradually more sophisticated. Gemcitabine and cisplatin combination therapy (or gemcitabine and oxaliplatin combination therapy) have become the standard of care for advanced biliary tract cancer. Oral fluoropyrimidines have also been shown to have good antitumor effects. Gemcitabine, platinum compounds, and oral fluoropyrimidines are now considered key drugs for the treatment of advanced biliary tract cancer. Several clinical trials using molecular targeted agents are also ongoing. Combination therapy using cytotoxic agents and molecular-targeted agents has been evaluated widely. However, reports regarding second-line chemotherapy remain limited, and it has not yet been clarified whether second-line chemotherapy can improve the prognosis of advanced biliary tract cancer. Thus, there is an urgent need to establish second-line standard chemotherapy treatment for advanced biliary tract cancer. Several problems exist when assessing the results of previous reports concerning advanced biliary tract cancer. In the present review, the current status of the treatment of advanced biliary tract cancer is summarized, and several associated problems are indicated. These problems should be solved to achieve more sophisticated treatment of advanced biliary tract cancer.

Keyword

Biliary tract neoplasms; Drug therapy

MeSH Terms

Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
Biliary Tract Neoplasms/*drug therapy/mortality/pathology
Disease Progression
Disease-Free Survival
Humans
Salvage Therapy
Time Factors
Treatment Outcome